| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FR-180204 | GDSC1000 | pan-cancer | AAC | -0.021 | 0.5 |
| mRNA | BRD-A94377914 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.5 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | 0.02 | 0.5 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | -0.022 | 0.5 |
| mRNA | LE-135 | CTRPv2 | pan-cancer | AAC | 0.022 | 0.5 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | -0.019 | 0.5 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | BMS-345541 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | -0.023 | 0.6 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |